Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

SESAUA 2024: Time Interval Between Radium-223 Therapy and 177Lu-PSMA Treatment for mCRPC and Outcomes in the RALU Study SESAUA 2024: State of the Art Lecture: Management of Complications Following ...

WCE 2019: Ambulatory Percutaneous Nephrolithotomy in Free - Standing Surgery Center: Outcomes of the First 550 Cases WCE 2019: Investigating the Role of Smaller Tract Percutaneous Nephrolithotomy in ...

Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no ...

WCET 2024, Prostate Cancer, robotic-assisted simple prostatectomy (RASP), Robotic Simple Prostatectomy Followed by Radiation Therapy Versus Robotic Radical Prostatectomy, Prostatomegaly, ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

AUA 2025 phase 3 CREST study, Sasanlimab in combination with BCG, transurethral resection of bladder tumor (TURBT), high-risk non-muscle-invasive bladder cancer.

Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 ...